Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 2/20 | 0.46 |
| ▸ | RXRB | P28702 | 1/20 | 0.41 |
| ▸ | RXRG | P48443 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 2/20 | 0.40 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 4/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL147802 | 0.92 | MRGPRX4 (0.44) | ATMMRGPRX4MEN1KMT2ANPC1 | |
| SCHEMBL141270 | 0.88 | MTNR1A (0.42) | ATMKMT2ANPC1GAARXFP1 | |
| SCHEMBL2512700 | 0.87 | NPC1 (0.41) | ATMMEN1KMT2ANPC1GAA | |
| SCHEMBL2519397 | 0.85 | NPC1 (0.46) | ATMMEN1KMT2ANPC1GAA | |
| SCHEMBL6216611 | 0.84 | HTT (0.50) | RXRARXRBRXRGMEN1KMT2A | |
| Hydrochloric Acid SCHEMBL3601686 | 0.84 | HDAC8 (0.44) | ATMMEN1KMT2ANPC1GAA | |
| SCHEMBL6220257 | 0.84 | HTT (0.43) | ATMMEN1KMT2ANPC1GAA | |
| SCHEMBL321478 | 0.83 | LMNA (0.46) | MEN1KMT2AGAAKDM4EALDH1A1 | |
| SCHEMBL2515131 | 0.81 | ALDH1A1 (0.45) | ATMMEN1KMT2ANPC1GAA | |
| SCHEMBL3587645 | 0.81 | HTT (0.45) | ATMMEN1KMT2ANPC1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8034828-B2 | Use of FGF inhibiting substituted 1,2,3 indolizine derivatives in the preparation of medicaments which can be used to treat diseases linked to pathological choroidal angiogenesis | SANOFI-AVENTIS (FR) | 2011-10-11 | — | — | US | claimed |
| US-20090030034-A1 | USE OF FGF INHIBITING SUBSTITUTED 1,2,3 INDOLIZINE DERIVATIVES IN THE PREPARATION OF MEDICAMENTS WHICH CAN BE USED TO TREAT DISEASES LINKED TO PATHOLOGICAL CHOROIDAL ANGIOGENESIS | SANOFI-AVENTIS (FR) | 2009-01-29 | — | — | US | claimed |
| US-7442708-B2 | 1,2,3-substituted indolizine derivatives, inhibitors of fgfs, method for making same and pharmaceutical compositions containing same | SANOFI-AVENTIS (FR) | 2008-10-28 | — | — | US | claimed |
| US-20050203126-A1 | Novel 1,2,3-substituted indolizine derivatives, inhibitors of fgfs, method for making same and pharmaceutical compositions containing same | SANOFI (FR) | 2005-09-15 | — | — | US | claimed |
| EP-1495023-B1 | NOVEL 1,2,3-SUBSTITUTED INDOLIZINE DERIVATIVES, INHIBITORS OF FGFS, METHOD FOR MAKING SAME AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | SANOFI AVENTIS (FR) | 2005-09-07 | — | — | EP | claimed |
| US-20140221455-A1 | DIFFERENTIATION MODULATING AGENTS AND USES THEREFOR | Verva Pharmaceuticals, Inc. (AU) | 2014-08-07 | — | — | US | disclosed |
| US-20120059047-A1 | DIFFERENTIATION MODULATING AGENTS AND USES THEREFOR | VERVA PHARMACEUTICALS PTY LTD (AU) | 2012-03-08 | — | — | US | disclosed |
| US-8034828-B2 | Use of FGF inhibiting substituted 1,2,3 indolizine derivatives in the preparation of medicaments which can be used to treat diseases linked to pathological choroidal angiogenesis | SANOFI-AVENTIS (FR) | 2011-10-11 | — | — | US | disclosed |
| US-7803811-B2 | 1,2,3-substituted indolizine derivatives, inhibitors of FGFs, method for preparing them and pharmaceutical compositions containing them | SANOFI-AVENTIS (FR) | 2010-09-28 | — | — | US | disclosed |
| US-20090030034-A1 | USE OF FGF INHIBITING SUBSTITUTED 1,2,3 INDOLIZINE DERIVATIVES IN THE PREPARATION OF MEDICAMENTS WHICH CAN BE USED TO TREAT DISEASES LINKED TO PATHOLOGICAL CHOROIDAL ANGIOGENESIS | SANOFI-AVENTIS (FR) | 2009-01-29 | — | — | US | disclosed |
| US-20090023770-A1 | Novel 1,2,3-Substituted Indolizine Derivatives, Inhibitors of FGFs, Method for Preparing Them and Pharmaceutical Compositions Containing Them | SANOFI-AVENTIS (FR) | 2009-01-22 | — | — | US | disclosed |
| US-7442708-B2 | 1,2,3-substituted indolizine derivatives, inhibitors of fgfs, method for making same and pharmaceutical compositions containing same | SANOFI-AVENTIS (FR) | 2008-10-28 | — | — | US | disclosed |
| US-20050282733-A1 | Differentiation modulating agents and uses therefor | VERVA PHARMACEUTICALS PTY LTD (AU) | 2005-12-22 | — | — | US | disclosed |
| US-20050203126-A1 | Novel 1,2,3-substituted indolizine derivatives, inhibitors of fgfs, method for making same and pharmaceutical compositions containing same | SANOFI (FR) | 2005-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050203126-A1 | Novel 1,2,3-substituted indolizine derivatives, inhibitors of fgfs, method for making same and pharmaceutical compositions containing same | FGFR3, FGFR1, NTRK3 | RXRA 829/4885RXRB 597/4885RXRG 563/4885 |
| US-20120059047-A1 | DIFFERENTIATION MODULATING AGENTS AND USES THEREFOR | FGF1, FABP4, FGF2 | RXRA 266/4885RXRB 197/4885RXRG 137/4885 |
| US-20090030034-A1 | USE OF FGF INHIBITING SUBSTITUTED 1,2,3 INDOLIZINE DERIVATIVES IN THE PREPARATION OF MEDICAMENTS WHICH CAN BE USED TO TREAT DISEASES LINKED TO PATHOLOGICAL CHOROIDAL ANGIOGENESIS | FGF1, FGF2, FGFR1 | RXRA 3227/4885RXRB 3256/4885RXRG 2856/4885 |
| US-20050282733-A1 | Differentiation modulating agents and uses therefor | FGF1, FABP4, FGF2 | RXRA 266/4885RXRB 197/4885RXRG 137/4885 |
| US-20090023770-A1 | Novel 1,2,3-Substituted Indolizine Derivatives, Inhibitors of FGFs, Method for Preparing Them and Pharmaceutical Compositions Containing Them | FGF2, FGF1, FGFR1 | RXRA 3192/4885RXRB 3193/4885RXRG 2579/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.